Earlier this month, the United States, Mexico, and Canada entered into the United States–Mexico–Canada Agreement, or USMCA, an updated version of the North American Free Trade Agreement. Since the details of the agreement were released, the pharmaceutical intellectual property portions of the deal have come under scrutiny.
Earlier this month, the United States, Mexico, and Canada entered into the United States—Mexico–Canada Agreement, or USMCA, an updated version of the North American Free Trade Agreement (NAFTA). Since the details of the agreement were released, the pharmaceutical intellectual property portions of the deal have come under scrutiny.
Under the newly negotiated deal, US drug companies will be able to sell pharmaceutical products in Canada for 10 years without facing generic or biosimilar competition. This is an increase from the 8 years of exclusivity under NAFTA.
Jim Keon, president of the Canadian Generic Pharmaceutical Association (CGPA), had concerns about this aspect of the agreement. “The pharmaceutical provisions in USMCA will delay access to competition from biosimilar biologic drugs. Biologic medicines represent the fastest growing cost segment of healthcare spending, and these delays will be costly to patients, business that sponsor employee drug plans, private payers and our industry,” he said.
Keon went on to discuss how the result of the agreement is disappointing for “the vast majority of Canadians who feel access to more affordable prescription medicines is the most important aspect of the negotiations.” Keon cited a recent poll conducted by Morning Consult for the CGPA from September 14-16, 2018, which found that 4 in 5 Canadians feel that it is important that the negotiations do not delay Canadians access to more affordable biologic drugs.
Conversely, the Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen J. Ubl spoke out in support of the agreement and specifically the intellectual property changes.
“The United States—Mexico–Canada Agreement marks a historic point for US trade policy, cementing critical intellectual property protections and other standards that will pave the way for the next generation of treatment and cures.” Ubl described intellectual property as the “lifeblood” of the biopharmaceutical industry and congratulated the Trump administration on the accomplishment of reaching such a “strong trade deal.”
This new agreement will not go into effect immediately. Most of the provisions are not set to begin until 2020 pending signatures from the leaders of the 3 countries and legislative approval.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.